Proteus Digital Health Presents Interim Results at ACC From a Randomized Controlled Clinical Study of Proteus Discover | Business Wire

CHICAGO–([SBP])–Proteus Digital Health presented interim results from a randomized

controlled study of Proteus Discover for patients with uncontrolled

hypertension and type 2 diabetes at the 65th Annual American College of

Cardiology meeting. Proteus Discover, a digital medicine offering,

consists of sensor-enabled medicines, a small wearable sensor patch.

applications for patients and clinical care givers. Proteus Discover

directly measures medication-taking and physiology to support patient

self-management and helps physicians and their care teams optimise

therapy. This study builds upon evidence gained through 66 studies

across diverse patient populations to assess accuracy, safety.

feasibility of use of Proteus Discover in patients with diseases such as

hypertension and diabetes.

Patients with uncontrolled hypertension, diabetes.

hypercholesterolemia are at high-risk for cardiovascular events and

costly interventions. Controlling these diseases has been shown to

reduce the risk of these complications.1,2 Nearly half of

patients with hypertension and type 2 diabetes fail to achieve treatment

goals. Medication non-adherence, poor patient engagement. Lack of

treatment optimization are major reasons for patients failing to achieve

their treatment goals.3-8The study enrolled

patients with these risk factors to understand whether a digital health

offering including digital medicines improves clinical outcomes and

treatment effectiveness.

This interim analysis revealed that patients with uncontrolled

hypertension and diabetes who used Proteus Discover achieved

statistically greater reduction in blood pressure (BP) and low-density

lipoprotein-cholesterol (LDL), known risk factors for cardiovascular

events. Were more likely to achieve their BP goal than usual care.

“The promising results from the pilot study demonstrate that this

innovative digital approach to therapy optimisation isn't only

patient-centered. Can lead to improved clinical outcomes,” said

George Savage, Chief Medical Officer of Proteus Digital Health. “The

findings suggest that deploying a panel of medicines that reflect the

needs of patients and physicians can move the needle in treatment

optimisation.”

In this 12-week, IRB-approved study, 96 patients (mean age 58; 50% male)

were enrolled with uncontrolled hypertension (systolic blood pressure

[SBP] ≥140 mm Hg) and type 2 diabetes (A1C ≥7%) who'd failed at least

two anti-hypertensive medications plus metformin and/or sulfonylurea.

Subjects received Proteus Discover for 4 or 12 weeks. usual care

based on a cluster randomized study design. The primary outcome was

change in SBP at week 4. Secondary outcomes included change in diastolic

blood pressure and proportion of subjects at BP target (

Proteus Digital Health
Robin Suchan, +1 650-637-6221
Corporate Communications
[email protected]